Validation of Selective Phytocannabinoids Using In Vitro Glaucoma Models
Glaucoma is the second leading cause of blindness in the world, mainly induced by increased pressure in the eye. Marijuana has been shown to reduce such pressure, thus benefit glaucoma patients. In the previous project, we screened several individual components from marijuana extracts and tested their ability on keeping cells alive. The current project puts an emphasis on neuroprotection and therapeutic aspects of glaucoma. We propose to target and analyse the effect of our selected compound for major downstream pathways that are significantly modulated in to Glaucoma pathology. These projects will provide pre-clinical data to support the compound possessing potential therapeutic value for the patients with Glaucoma in the future.